Nath Bio-Genes (India) Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹250 Cr
- P/E
- 7.37
- ROE
- 5.33%
- PEG
- 28.36
- Price to sales
- 0.50
- Debt to equity
- 0.20
- 52W high / low
- ₹196 / ₹129
- EBITDA margin
- 10.07%
- Net profit margin
- 9.85%
- Promoter holding
- 45.59%
- Sales (last year)
- ₹490 Cr
Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds[1]
Guidance scorecard · Q1 FY27 call
What Nath Bio-Genes (India) Ltd's management guided
and where it ranks in Agricultural Food & other Products
RevenueQ4 FY26 call
10–20%- Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26.
- Paddy volume growth is anticipated at 20-25%, reflecting strong performance.
- Maize is a key growth driver, with significant volume surge of 54% in FY26 and expected to maintain strong growth.
- Overall top-line (revenue) growth for FY27 is conservatively projected between 15-20%.
- EBITDA margins and net profit margins are expected to maintain a slight upward trend.
- The company is confident in scaling operations sustainably, backed by a stable production base, growing market presence, and robust product pipeline.
2 more points from Nath Bio-Genes (India) Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what Nath Bio-Genes (India) Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
None planned- Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.
- The company avoids heavy investments in processing plants and storage facilities, opting instead for rentals, as the need for such infrastructure is limited and seasonal (e.g., maize requires about 15-20 days of processing).
- For FY27, there are no significant planned CapEx investments in processing capacity, cold storage, or new geographies.
- The strategy favors minimal CapEx with an emphasis on operational efficiency and leveraging existing external infrastructures rather than owning them.
FundraisingQ4 FY26 call
See what Nath Bio-Genes (India) Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- Inventory has increased as the company is building stock ahead of the upcoming season, expecting sales to liquidate the inventory over the next two years.
- Production is being stabilized with improved yield, contributing to increased sales (cotton Bt volume grew 22% YoY).
- The company anticipates top-line growth of 15-20% for FY27, reflecting confidence in demand.
2 more points from Nath Bio-Genes (India) Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Agricultural Food & other Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Agricultural Food & other Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 0–2% | ₹911 Cr | 14.0 | |
| 2 | 40%+ | Up 0–2% | ₹129 Cr | 7.0 | |
| 3 | 40%+ | Flat | ₹23 Cr | 9.5 | |
| 4 | 20–40% | Up 2%+ | ₹219 Cr | 15.0 | |
| 5 | 20–40% | Up 2%+ | ₹190 Cr | 17.9 | |
| 6 | 20–40% | Up 0–2% | ₹2,595 Cr | 33.0 |
Sign up free to see every company in the sector ranking and track Nath Bio-Genes (India) Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Agricultural Food & other Products rankingFinancials of Nath Bio-Genes (India) Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Nath Bio-Genes (India) Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 44.99 | 235.28 | 22.57 | 31.74 | 43.04 | 243.88 | 32.19 | 36.87 | 51.97 | 283.70 | 43.85 | 65.96 | 51.59 |
| Expenses + | 41.06 | 198.26 | 17.58 | 26.09 | 39.11 | 207.34 | 27.38 | 28.83 | 51.55 | 245.41 | 37.74 | 62.39 | 47.11 |
| Operating Profit | 3.93 | 37.02 | 4.99 | 5.65 | 3.93 | 36.54 | 4.81 | 8.04 | 0.42 | 38.29 | 6.11 | 3.57 | 4.48 |
| OPM % | 8.74% | 15.73% | 22.11% | 17.80% | 9.13% | 14.98% | 14.94% | 21.81% | 0.81% | 13.50% | 13.93% | 5.41% | 8.68% |
| Other Income + | 0.26 | 0.12 | 0.06 | 2.54 | 1.36 | 0.13 | 0.08 | 0.48 | 4.40 | 3.83 | 4.00 | 4.42 | 3.63 |
| Interest | 1.53 | 2.76 | 2.44 | 2.84 | 1.07 | 2.24 | 2.98 | 3.90 | 1.37 | 3.20 | 3.66 | 4.54 | 4.59 |
| Depreciation | 0.99 | 0.76 | 0.76 | 0.76 | 0.98 | 0.83 | 0.83 | 0.83 | 1.34 | 0.98 | 0.99 | 0.98 | 1.03 |
| Profit before tax | 1.67 | 33.62 | 1.85 | 4.59 | 3.24 | 33.60 | 1.08 | 3.79 | 2.11 | 37.94 | 5.46 | 2.47 | 2.49 |
| Tax % | 13.77% | 0.65% | 18.92% | 16.78% | 19.14% | 0.74% | -2.78% | 30.08% | 29.86% | 1.74% | 11.72% | 35.22% | 100.40% |
| Net Profit + | 1.43 | 33.41 | 1.50 | 3.82 | 2.62 | 33.35 | 1.11 | 2.65 | 1.48 | 37.28 | 4.82 | 1.60 | -0.01 |
| EPS in Rs | 0.76 | 17.59 | 0.79 | 2.02 | 1.38 | 17.55 | 0.58 | 1.39 | 0.78 | 19.62 | 2.54 | 0.84 | -0.01 |
Financials of Nath Bio-Genes (India) Ltd
Profit & Loss
Annual income statement trend
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 97 | 109 | 230 | 234 | 248 | 268 | 445 |
| Expenses + | 82 | 89 | 193 | 185 | 198 | 217 | 393 |
| Operating Profit | 15 | 20 | 37 | 49 | 50 | 51 | 52 |
| OPM % | 15% | 18% | 16% | 21% | 20% | 19% | 12% |
| Other Income + | 1 | 1 | -87 | 1 | 4 | 4 | 14 |
| Interest | 2 | 4 | 11 | 10 | 9 | 11 | 16 |
| Depreciation | 5 | 5 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 9 | 12 | -63 | 36 | 42 | 41 | 46 |
| Tax % | -1% | 4% | 6% | 3% | 5% | 5% | 10% |
| Net Profit + | 9 | 12 | -67 | 35 | 40 | 39 | 42 |
| EPS in Rs | 5.75 | 7.34 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 |
| Dividend Payout % | 0% | 0% | -6% | 11% | 10% | 10% | 9% |
Financials of Nath Bio-Genes (India) Ltd
Balance Sheet
Capital structure and asset base
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 30 | 41 | 523 | 554 | 591 | 625 | 661 |
| Borrowings + | 11 | 19 | 93 | 105 | 110 | 123 | 138 |
| Other Liabilities + | 63 | 82 | 105 | 114 | 160 | 259 | 278 |
| Total Liabilities | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
| Fixed Assets + | 21 | 38 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 5 | 5 | 6 | 6 | 6 |
| Other Assets + | 99 | 121 | 490 | 543 | 625 | 770 | 842 |
| Total Assets | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
Financials of Nath Bio-Genes (India) Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 17 | 38 | 75 | 18 | -13 | ||
| Cash from Investing Activity + | -20 | -3 | -27 | -4 | 3 | ||
| Cash from Financing Activity + | -22 | -2 | -8 | -2 | -4 | ||
| Net Cash Flow | -25 | 34 | 39 | 11 | -13 | ||
| Free Cash Flow | 16 | 36 | 48 | 10 | -16 | ||
| CFO/OP | 54% | 80% | 150% | 37% | -22% |
Financials of Nath Bio-Genes (India) Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 70 | 136 | 152 | 139 | 121 | 70 |
| Inventory Days | 587 | 667 | 4,388 | ||||
| Days Payable | 146 | 239 | 586 | ||||
| Cash Conversion Cycle | 487 | 499 | 136 | 3,954 | 139 | 121 | 70 |
| Working Capital Days | 79 | 64 | 427 | 415 | 342 | 321 | 253 |
| ROCE % | 24% | 7% | 7% | 7% | 7% |
Guidance history
How Nath Bio-Genes (India) Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 10–20% | Flat | None planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY25 call → | 10–20% | Flat | None planned | None planned | Flat |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Nath Bio-Genes (India) Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
Others in Agricultural Food & other Products this season
- Norben Tea (Q2 FY27)
Revenue from Operations for the quarter ended 30th September 2026 is ₹273.48 lakhs, compared to ₹238.93 lakhs for the quarter ended 30th September 2025…
- Upsurge Seeds (Q2 FY27)
Revenue from operations for the half year ended 30th September 2026 is ₹13,679.33 lakhs. Key results statement takeaways from Upsurge Seeds of Agriculture Ltd's
- Shree Renuka Sugars Ltd (Q2 FY27)
Year-on-year revenue increase: INR 6,130 million (approximately 34.5% increase) . Key results statement takeaways from Shree Renuka Sugars Ltd's Q2 FY27 results
- Sayaji Industries Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹288 crore . Key investor presentation takeaways from Sayaji Industries Ltd's Q1 FY27 investor presentation — and how it ran